Effect of Vasoactive Intestinal Polypeptide on Development of Migraine Headaches

• DOI: 10.1001/jamanetworkopen.2021.18543
• Publication Date: 2021-08-06T11:32:29Z
• Authors: Lanfranco Pellesi; Mohammad Al-Mahdi...; Roberto De Icco; Hande Coskun; Fatima Azzahra El...; Cristina Lopez-Lopez; Josefin Snellman; Jens Hannibal; Faisal Mohammad Amin; Messoud Ashina
• Keywords: Crossover study

<h3>Importance</h3> Vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase-activating polypeptides (PACAPs) are structurally functionally related, yet different in their migraine-inducing properties. It remains unclear whether the lack of migraine induction can be attributed to only transient vasodilatory response after a 20-minute infusion VIP. <h3>Objective</h3> To determine 2-hour VIP would provoke attacks. <h3>Design, Setting, Participants</h3> A randomized, double-blind, placebo-controlled, crossover study was conducted between May September 2020 at Danish Headache Center Copenhagen, Denmark. Patients were eligible for inclusion if they ages 18 40 years, weighed 50 90 kg, had diagnosis without aura as defined by International Classification Disorders, frequency 1 6 attacks per month. <h3>Interventions</h3> randomly allocated receive or placebo on 2 days. <h3>Main Outcomes Measures</h3> The primary end point difference incidence experimentally induced during observational period (0-12 hours) placebo. <h3>Results</h3> Twenty-one patients (17 [81%] women 4 [19%] men; mean [range] age, 25.9 [19-40] years) recruited study. Fifteen (71%; 95% CI, 48%-89%) developed compared with patient (5%; 0%-24%) who attack (<i>P</i> &lt; .001). VIP-induced mimicked patients' spontaneous area under curve (AUC) headache intensity scores hours), well AUC superficial temporal artery diameter (0-180 minute) significantly greater (AUC_0-12h,<i>P</i> = .003; AUC_0-180min,<i>P</i> <h3>Conclusions Relevance</h3> caused attacks, suggesting an important role pathophysiology. its receptors could potential targets novel drugs. <h3>Trial Registration</h3> ClinicalTrials.gov Identifier:NCT04260035